Fund Companies Rights Offerings Managed Distributions Leveraged Funds IPOs Asset Classes CEF Advisors

My Fund Comparison
Initilizing list...

Tekla Healthcare Investors  as of 05/24/2017

NYSE / HQH Asset Class:  Sector Equity Funds 1 YR Lipper Avg:  13.01%

Growth of $10K

Avg Annual Total Return %
  10 YR 5 YR 1 YR YTD
Market Return 12.28% 18.98% 7.07% 21.71%
Lipper Pct. Rank 38 16 71 18
NAV Return 10.89% 16.14% 7.12% 12.29%
Lipper Pct. Rank 38 37 57 32
Premium/Discount History

Premium/Discount
10 YR Avg 5 YR Avg YTD Avg
-7.539% -1.845% -3.180%

NAV $24.94 Market Price $25.24
Net Change -$0.01 Market Change -$0.13
Premium/Discount 1.20%
1 YR NAV Return 7.119%
1 YR NAV Rank 57
12-Mo Yield as of 4/30/2017 Yield Def
Income Only Yield 0.00%
Distribution Yield (Market) 7.56%
Most Recent Income Dividend $0.470
Ex-Div Date 8/25/2016
Most Recent Cap Gain Dividend $0.450
Ex-Div Date 2/24/2017
Dividend Frequency Quarterly
YTD Dividends --
YTD Capital Gains $0.450
Inception Date 4/23/1987
Fund Advisor Tekla Capital Management LLC
Manager & Tenure Team Managed
Phone 800-451-2597
Website www.teklacap.com
Total Net Assets (mil) as of -- --
% Leveraged Assets as of 9/30/2016 --
Portfolio Turnover 29.00%
Mgmt Fees 0.934%
Expense Ratio 1.100%
Fund Objective
The Fund seeks long-term capital appreciation by investing primarily in securities of companies in the health services and medical technology (health care) industries ("Health care Companies").
Top Holdings (as of 9/30/2016)
Gilead Sciences Inc ORD 8.10%
Celgene Corp ORD 7.37%
Biogen Inc ORD 7.03%
Incyte Corp ORD 4.92%
Regeneron Pharmaceuticals Inc ORD 4.52%
Alexion Pharmaceuticals Inc ORD 4.39%
Vertex Pharmaceuticals Inc ORD 4.25%
Allergan plc ORD 4.04%
Biomarin Pharmaceutical Inc ORD 3.86%
Illumina Inc ORD 3.23%
Top Sectors (as of 9/30/2016)
Health Care 90.37%
Non Classified Equity 3.56%
Consumer Services 1.56%
Industrials 1.02%


Resources

Aberdeen Closed-End TV

Asset TV - CEF Channel

CEF Connect

Bonds

REITs

Seeking Alpha CEF Articles
SySys Logo

Lipper Logo
Powered by a SySys data & content management system.

© Thomson Reuters 2011. All rights reserved. Any copying, republication or redistribution of Lipper, a Thomson Reuters company, content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper, a Thomson Reuters company. Lipper, a Thomson Reuters company shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.